Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

The Lancet Neurology

Fecha de publicación: Noviembre de 2021

Autores: Prof Tanuja Chitnis, MD , Prof Brenda Banwell, MD, Prof Ludwig Kappos, MD, Prof Douglas L Arnold, MD, Prof Kivilcim Gücüyener, MD, Kumaran Deiva, MD, Prof Natalia Skripchenko, MD, Prof Li-Ying Cui, MD, Stephane Saubadu, MD, Wenruo Hu, MPH, Myriam Benamor, MD, Annaig Le-Halpere, PharmD, Philippe Truffinet, MD, Prof Marc Tardieu, MD, on behalf of theTERIKIDS Investigators


Background: Therapeutic options for children with multiple sclerosis are scarce. Teriflunomide is approved in more than 80 countries for the treatment of adults with relapsing multiple sclerosis. The TERIKIDS study examined the safety and efficacy of teriflunomide in children with relapsing multiple sclerosis.

Enviar comentario